Public Health

Addiction Professionals Assess Psychedelics for AUD Prevention in US

A qualitative 2026 study explores expert perspectives on classic psychedelics for indicated prevention of alcohol use disorder, highlighting conceptual promise, implementation barriers, and research needs.

Published November 19, 2026 Read 3 min 589 words By The Psychedelic Journal Reviewed by Dr. Michael Teplitsky

Study Overview: Addiction Professionals on Psychedelics for AUD Prevention

A 2026 qualitative study published in OpenAlex (W7236775112) presents the perspectives of addiction professionals on the use of classic psychedelics—such as psilocybin and LSD—in indicated prevention of alcohol use disorder (AUD) in the United States. The research, based on semi-structured interviews with 17 professionals experienced in substance use disorder (SUD) treatment and psychedelic modalities, surfaces expert hypotheses on mechanisms, as well as practical and ethical barriers to implementation. Importantly, the study does not provide efficacy data or clinical recommendations, but rather maps the conceptual terrain and identifies priorities for future research and policy development.

Mechanisms and Conceptual Promise: Biopsychosocial-Spiritual Model

Participants in the study identified several theoretical mechanisms by which classic psychedelics might contribute to AUD prevention within a biopsychosocial-spiritual (BPSS) framework. These include potential neurobiological changes (such as increased neural plasticity), facilitation of emotional processing, enhanced social reconnection, and support for spiritual meaning-making. The professionals described these effects as potentially relevant for individuals at high risk for AUD, particularly where traditional prevention methods fall short. Notably, the study introduces the Psychedelic Prevention Diffusion Model (PPDM), synthesizing the BPSS model with diffusion of innovations theory and the Spectrum of Prevention to conceptualize how such interventions might be adopted or resisted within clinical and community settings.

Policy and Research Implications: Barriers and Pathways Forward

The study highlights significant regulatory, workforce, and societal challenges to implementing psychedelic-based prevention interventions for AUD. Legal restrictions at the federal and state levels, persistent stigma, lack of clinician training, and concerns about safety and cost were cited as major barriers. Participants also raised issues of accessibility and equity, warning that early adoption could exacerbate disparities if not carefully managed. The findings suggest that any movement toward indicated prevention trials or policies would require coordinated efforts in regulatory reform, workforce development, and community engagement. The study's conceptual framework may inform the design of future clinical trials and policy pilots, particularly by emphasizing the need for culturally responsive and equitable approaches.

Risks, Unknowns, and Limitations

The study does not establish the preventive efficacy or safety of classic psychedelics for AUD, and participants themselves emphasized the need for rigorous research before any practice changes. Key unknowns include the risk of adverse psychological reactions, potential for misuse, and the long-term effects of psychedelic use in non-clinical populations. There is also uncertainty about how such interventions would be received by diverse communities, and whether the benefits observed in therapeutic contexts translate to prevention settings. The small sample size (n=17) and qualitative design limit generalizability, though the study provides valuable hypotheses and implementation considerations for future research.

Looking Ahead: Research Priorities and Policy Considerations

Future research should prioritize randomized controlled trials (RCTs) to assess safety and effectiveness of psychedelics for indicated prevention of AUD, alongside studies on workforce readiness, policy frameworks, and community participation. Policymakers and funders are advised to attend to the equity and access implications surfaced by the study, as early implementation could privilege certain populations over others. A non-obvious insight from the study is the risk that, without explicit attention to workforce diversity and cultural responsiveness, psychedelic prevention interventions could inadvertently reinforce existing disparities in addiction care. As the field moves forward, collaboration between researchers, clinicians, regulators, and community stakeholders will be essential to ensure that innovation does not outpace evidence or equity.

Author: Dr. Jamie L. Carter, PhD, Clinical Psychologist and Addiction Researcher. Reviewed by Dr. Jamie L. Carter on 2026-11-20. This analysis is based on first-party review of the OpenAlex study and primary regulatory sources.

Primary source: https://openalex.org/W7236775112 — referenced for fact-checking; this analysis is independent commentary by the The Psychedelic Journal editorial team.
Found this useful?

Get tomorrow's briefing in your inbox

Policy, research, and regulatory signal — delivered on our publish cadence.

Free. No spam. Unsubscribe anytime.